Novo Nordisk’s semaglutide is headed toward a Lilly showdown. Will Novo speed it up?

Novo Nordisk is considering using a priority review voucher for the candidate, a company spokesman confirmed by email. Doing so would expedite semaglutide’s trip down the regulatory pathway—and hasten a head-to-head battle in the diabetes sphere with dru